Neurocrine Biosciences (NBIX) News Today $137.00 -2.43 (-1.74%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$136.53 -0.47 (-0.35%) As of 10/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Truist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIX1 hour ago | marketbeat.comNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial ResultsOctober 7 at 4:01 PM | prnewswire.comNeurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry FranchiseOctober 7 at 11:27 AM | finance.yahoo.comA Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study ResultsOctober 7 at 11:27 AM | finance.yahoo.comNeurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc.October 7 at 4:02 AM | marketbeat.comNeurocrine presents new data from KINECT-HD2 study of ingrezzaOctober 6 at 1:36 PM | msn.comNeurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington ...October 6 at 1:36 PM | finance.yahoo.comNeurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease ChoreaOctober 6 at 8:30 AM | prnewswire.comPure Financial Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIXOctober 4, 2025 | marketbeat.comWashington Capital Management Inc. Purchases 1,800 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 29, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Raises Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 28, 2025 | marketbeat.comShould You be Optimistic on Neurocrine Biosciences (NBIX)?September 25, 2025 | insidermonkey.comShould You be Optimistic on Neurocrine Biosciences (NBIX)?September 25, 2025 | finance.yahoo.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by Assenagon Asset Management S.A.September 24, 2025 | marketbeat.comNeurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease BurdenSeptember 23, 2025 | prnewswire.comPromising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine BiosciencesSeptember 23, 2025 | tipranks.comAvanza Fonder AB Sells 9,207 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 23, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given "Outperform" Rating at WedbushSeptember 22, 2025 | marketbeat.comWhere Neurocrine Biosciences Stands With AnalystsSeptember 22, 2025 | benzinga.comNeurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive DisorderSeptember 22, 2025 | prnewswire.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $170.00 at Needham & Company LLCSeptember 22, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 22, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Purchased by Atle Fund Management ABSeptember 21, 2025 | marketbeat.comFulton Bank N.A. Invests $333,000 in Neurocrine Biosciences, Inc. $NBIXSeptember 21, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Stock Holdings Raised by Swedbank ABSeptember 19, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Acquired by Pallas Capital Advisors LLCSeptember 19, 2025 | marketbeat.com5,541 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Financiere des Professionnels Fonds d investissement inc.September 18, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TranscriptSeptember 17, 2025 | seekingalpha.comNeurocrine Biosciences, Inc. $NBIX Shares Acquired by Voya Investment Management LLCSeptember 17, 2025 | marketbeat.comWhat Does Wall Street Think About Neurocrine Biosciences (NBIX)?September 16, 2025 | msn.comNeurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025September 16, 2025 | prnewswire.comJuncture Wealth Strategies LLC Sells 2,766 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 16, 2025 | marketbeat.comCity Center Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIXSeptember 16, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Holdings Cut by First Hawaiian BankSeptember 16, 2025 | marketbeat.comSwedbank AB Raises Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 15, 2025 | marketbeat.comIntech Investment Management LLC Has $3.96 Million Stake in Neurocrine Biosciences, Inc. $NBIXSeptember 15, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIXSeptember 15, 2025 | marketbeat.comIntegrated Wealth Concepts LLC Buys 4,526 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 15, 2025 | marketbeat.comPlato Investment Management Ltd Has $255,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIXSeptember 14, 2025 | marketbeat.comWoodline Partners LP Invests $14.70 Million in Neurocrine Biosciences, Inc. $NBIXSeptember 13, 2025 | marketbeat.comGreat Lakes Advisors LLC Has $3.54 Million Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 13, 2025 | marketbeat.comVident Advisory LLC Invests $202,000 in Neurocrine Biosciences, Inc. $NBIXSeptember 13, 2025 | marketbeat.comUnited Services Automobile Association Makes New $741,000 Investment in Neurocrine Biosciences, Inc. $NBIXSeptember 11, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Up 39.6% in AugustSeptember 10, 2025 | marketbeat.comTeza Capital Management LLC Sells 12,560 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 10, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires 21,726 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 10, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by AmundiSeptember 10, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comParkman Healthcare Partners LLC Has $18.62 Million Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 8, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by EFG Asset Management North America Corp.September 7, 2025 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.680.55▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼818▲NBIX Articles Average Week Get the Latest News and Ratings for NBIX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Biogen News Today United Therapeutics News Today Incyte News Today Ionis Pharmaceuticals News Today Exact Sciences News Today Exelixis News Today BioMarin Pharmaceutical News Today Madrigal Pharmaceuticals News Today Repligen News Today Halozyme Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
